Oncology

The CRL indicates that the ALLELE clinical trial does not sufficiently show efficacy of the product.

Review top news and interview highlights from the week ending January 9, 2026.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

We highlighted a few cell and gene therapies that are nearing or likely nearing key FDA decisions in the first half of 2026.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about the potential of AI to affect development and use of cell and gene therapy products.

Take a look what stood out as pillars of progress and success from all of CGTLive's most popular oncology stories in 2025.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, on cost reduction for cell and gene therapy products.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed their thoughts on the field's future.

Recapping some the FDA approvals and regulatory updates in cell and gene therapy that made waves in 2025.

The trial is open to patients with a wide array of solid tumor indications.

Review top news and interview highlights from the week ending December 19, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, on the importance of big wins for those in research.

Review top news and interview highlights from the week ending December 12, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The Fondazione Telethon agent, etuvetidigene autotemcel, significantly reduced severe infections and bleeding events in clinical studies.

Deevyashali Parekh, MBBS, an internal medicine resident at SUNY Upstate Medical University Hospital, discussed findings from a patient population traditionally excluded from clinical trials for CAR-T.

ImmunoLogic cohost Janna Minehart, MD, discussed a few exciting immunotherapy sessions she attended at ASH's Annual Meeting.

AZD0120, a dual-targeted CAR T-cell therapy, shows high efficacy in treating relapsed multiple myeloma, achieving a 96% response rate.

Review top news and interview highlights from the week ending December 5, 2025.

The agency's decision was based on results from an r/r MZL cohort in the phase 2 TRANSCEND FL clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed lessons that should guide the next generation of developers and regulators entering the field.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.